Cardiovascular · HRT
HRT and cholesterol: what actually happens to your lipids
Menopause is a lipid event. Within 12 months of the final period, LDL rises ~10–15% and small dense LDL particles increase. HRT reverses most of this — but the route (oral vs transdermal) matters enormously for the risk-benefit calculation.
What menopause does to lipids
Estrogen upregulates the hepatic LDL receptor, keeping circulating LDL low. As estrogen falls, LDL rises, HDL falls modestly, and the LDL particles themselves shift toward the small-dense phenotype that penetrates arterial walls more readily. This is why cardiovascular risk in women accelerates sharply in the decade after menopause.
Oral vs transdermal — a critical distinction
Oral estrogen passes through the liver first, which triggers larger lipid changes (LDL down more, HDL up more) but also raises triglycerides, CRP, and clotting factors. Transdermal estradiol enters bloodstream directly, giving modest lipid improvement without the pro-thrombotic profile. For any woman with cardiovascular risk, family history of clots, or elevated triglycerides — transdermal is the answer.
Expected changes on transdermal estradiol
- LDL: down 5–10%
- HDL: up 3–5%
- Triglycerides: unchanged or slightly down
- Lp(a): often down 15–20%
- CRP: unchanged (oral raises it)
Practical protocol
Check a full lipid panel and ApoB before starting. Recheck at 3 and 12 months. If ASCVD 10-year risk is above 7.5%, HRT is not a substitute for a statin — but both can be used together, and transdermal HRT does not compete with statin benefit.
Frequently asked questions
Does HRT raise or lower cholesterol?
HRT lowers LDL and raises HDL. Oral estrogen has larger lipid effects but raises triglycerides and clotting risk. Transdermal estradiol produces modest lipid improvement without those risks.
Should I take HRT if I have high cholesterol?
HRT is not contraindicated by high cholesterol. In perimenopausal women with high LDL, transdermal estradiol often improves the lipid panel. Statins remain first-line for elevated ASCVD risk.
Does HRT prevent heart disease?
Started within 10 years of menopause, HRT is associated with reduced cardiovascular events. Started 10+ years post-menopause, it is not protective and may increase early events.
Is transdermal or oral HRT safer for the heart?
Transdermal. It bypasses first-pass hepatic metabolism, so it does not raise triglycerides, CRP, or clotting factors. Transdermal is preferred in women with any cardiovascular risk.
Can HRT replace a statin?
No. Statins address a different mechanism (LDL receptor upregulation) and have direct cardiovascular event data HRT lacks. They complement each other when both indicated.
Considering a physician-supervised longevity protocol? Kindr Health evaluates peptide therapy as part of personalized perimenopause and menopause care.
Request your Longevity Consult →Related: FDA peptide review July 2026 briefing · Peptide therapy hub · Longevity service
Medically reviewed by Kindr Health Clinical Team · Last reviewed 2026-06-19. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products.